<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02159729</url>
  </required_header>
  <id_info>
    <org_study_id>ATX-101-08-12</org_study_id>
    <nct_id>NCT02159729</nct_id>
  </id_info>
  <brief_title>Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101</brief_title>
  <official_title>Long-term Follow-up Study of Subjects Who Completed Kythera-sponsored Trials of ATX-101 (Sodium Deoxycholate Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kythera Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kythera Biopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long-term follow-up study of subjects who completed Kythera-sponsored trials of ATX-101
      (06-03, 07-07, 09-15)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No study medication was administered in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by number of adverse events</measure>
    <time_frame>up to 60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessments using a clinician rating scale</measure>
    <time_frame>up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessments using patient reported scales</measure>
    <time_frame>up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessments using a laxity scale</measure>
    <time_frame>up to 60 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Efficacy assessments based on standardized photography</measure>
    <time_frame>up to 60 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Efficacy assessments on submental fat using calipers</measure>
    <time_frame>up to 60 months</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">205</enrollment>
  <condition>Submental Fat</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects treated with placebo in previous ATX-101 studies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATX-101 (1 mg/cm2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects treated with ATX-101 (1 mg/cm2) in previous phase 2 studies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATX-101 (2 mg/cm2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects treated with ATX-101 (2 mg/cm2) in previous phase 2 studies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ATX-101 (4 mg/cm2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects treated with ATX-101 (4 mg/cm2) in previous phase 2 studies</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATX-101 (1 mg/cm2)</intervention_name>
    <description>Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events</description>
    <arm_group_label>ATX-101 (1 mg/cm2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATX-101 (2 mg/cm2)</intervention_name>
    <description>Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events</description>
    <arm_group_label>ATX-101 (2 mg/cm2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATX-101 (4 mg/cm2)</intervention_name>
    <description>Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events</description>
    <arm_group_label>ATX-101 (4 mg/cm2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any subject who successfully completed a Kythera-sponsored clinical trial of ATX-101
             (06-03, 07-07, 09-15)

          -  Signed informed consent

          -  Willingness to comply with schedule and procedures of the study

        Exclusion Criteria:

          -  Subjects who have had or are undergoing treatment that may affect the evaluation of
             the submental area will be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederick Beddingfield, III, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Total Skin &amp; Beauty Dermatology Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Testing Center Beverly Hills</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mokusiga, Inc</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plastic &amp; Reconstructive Surgery</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Institute of DuPage Medical Group in Naperville</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Care Physicians</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Body Aesthetic Research Center</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialists, PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mei-Heng Tan</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Centre, AHC House</name>
      <address>
        <city>Benowa</city>
        <state>Queensland</state>
        <zip>4217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Dermatology Belmont Specialist Centre</name>
      <address>
        <city>Carina Heights</city>
        <state>Queensland</state>
        <zip>4152</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>T/AS Dermatology Institute of Victoria</name>
      <address>
        <city>South Yarra</city>
        <state>Victoria</state>
        <zip>3141</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niagara Falls Dermatology &amp; Skin Care</name>
      <address>
        <city>Niagara Falls</city>
        <state>Ontario</state>
        <zip>L2E 7H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Cosmetic &amp; Laser Surgery</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Cosmetic Skin Surgery Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4V 1R1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cosmetic Dermatology on Bloor</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 3B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Dermatology Centre</name>
      <address>
        <city>Salford</city>
        <state>Manchester</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cranley Clinic, Harcout House</name>
      <address>
        <city>London</city>
        <zip>W1G OPN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2014</study_first_submitted>
  <study_first_submitted_qc>June 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2014</study_first_posted>
  <last_update_submitted>May 5, 2016</last_update_submitted>
  <last_update_submitted_qc>May 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

